Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235788 | 0.95 | KDM4E (0.41) | KDM4EMAPK8PNPALDH1A1MAPT | |
| SCHEMBL5238679 | 0.88 | ALDH1A1 (0.50) | KDM4EMAPK8ALDH1A1MAPTGAA | |
| SCHEMBL5239883 | 0.88 | PTGDR2 (0.40) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL5276033 | 0.86 | KDM4E (0.52) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL5236157 | 0.86 | RORA (0.41) | KDM4EALDH1A1MAPTNPC1HPGD | |
| SCHEMBL5236394 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL5237473 | 0.84 | ALDH1A1 (0.41) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL5233862 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1MAPTGAALMNA | |
| SCHEMBL5576875 | 0.84 | ALDH1A1 (0.50) | KDM4EMAPK8ALDH1A1MAPTGAA | |
| SCHEMBL5235266 | 0.83 | TNF (0.42) | KDM4EALDH1A1MAPTGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070117840-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1604983-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1355886-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062764-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | KDM4E 897/4885MAPK8 2612/4885PNP 2389/4885 |
| US-20070117840-A1 | Receptor antagonist | FSHR, NR4A1, GHRHR | KDM4E 2749/4885MAPK8 1528/4885PNP 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.